Scancell (LON:SCLP) Shares Down 3.2% - What's Next?

Key Points

• Shares of Scancell Holdings plc dropped by 3.2% during mid-day trading, with the stock trading as low as GBX 9.60 ($0.13).
• The company has a market cap of £100.51 million and a price-to-earnings ratio of -465.63, indicating significant financial challenges.
• Insider Martin Diggle purchased 102,236 shares at an average price of GBX 11 per share, demonstrating confidence in the company's future despite the current stock decline.

Shares of Scancell Holdings plc (LON:SCLP - ) traded down 3.2% during mid-day trading on Tuesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). 1,336,894 shares were traded during mid-day trading, an increase of 44% from the average session volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Down 3.2%

The firm's fifty day moving average price is GBX 10.17 and its 200-day moving average price is GBX 9.61. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The company has a market cap of £100.51 million, a price-to-earnings ratio of -465.63 and a beta of 0.35.

Insider Activity at Scancell

In related news, insider Martin Diggle bought 102,236 shares of Scancell stock in a transaction that occurred on Thursday, August 7th. The stock was acquired at an average price of GBX 11 per share, with a total value of £11,245.96. Insiders own 14.23% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.